SCI Pharmtech, Inc. (4119.TW)
TWD 70.9
(-2.48%)
TWD 70.9
(-2.48%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 845.52 Million TWD | 95.47% |
| 2022 | 432.55 Million TWD | 75653.24% |
| 2021 | 571 Thousand TWD | -54.25% |
| 2020 | 1.24 Million TWD | 4.26% |
| 2019 | 1.19 Million TWD | 0.0% |
| 2018 | - TWD | 0.0% |
| 2017 | - TWD | 0.0% |
| 2016 | - TWD | 0.0% |
| 2015 | - TWD | -100.0% |
| 2014 | 576.94 Million TWD | 2.43% |
| 2013 | 563.26 Million TWD | 0.0% |
| 2012 | - TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 915.12 Million TWD | 8.31% |
| 2024 Q2 | 868.38 Million TWD | -4.86% |
| 2023 Q4 | 845.52 Million TWD | 14.4% |
| 2023 Q2 | 592.4 Million TWD | 17.94% |
| 2023 Q3 | 739.12 Million TWD | 24.77% |
| 2023 FY | 845.52 Million TWD | 95.47% |
| 2023 Q1 | 502.31 Million TWD | 16.13% |
| 2022 Q4 | 432.55 Million TWD | 101.78% |
| 2022 Q3 | 214.36 Million TWD | 33.29% |
| 2022 FY | 432.55 Million TWD | 75653.24% |
| 2022 Q2 | 160.82 Million TWD | 48.03% |
| 2022 Q1 | 108.64 Million TWD | 18926.97% |
| 2021 Q2 | 1.32 Million TWD | 34.51% |
| 2021 Q4 | 571 Thousand TWD | -37.53% |
| 2021 FY | 571 Thousand TWD | -54.25% |
| 2021 Q1 | 988 Thousand TWD | -20.83% |
| 2021 Q3 | 914 Thousand TWD | -31.23% |
| 2020 FY | 1.24 Million TWD | 4.26% |
| 2020 Q3 | 1.49 Million TWD | 140.65% |
| 2020 Q4 | 1.24 Million TWD | -16.35% |
| 2020 Q1 | 815 Thousand TWD | -31.91% |
| 2020 Q2 | 620 Thousand TWD | -23.93% |
| 2019 Q1 | 1.77 Million TWD | 0.0% |
| 2019 FY | 1.19 Million TWD | 0.0% |
| 2019 Q4 | 1.19 Million TWD | 20.18% |
| 2019 Q3 | 996 Thousand TWD | -25.84% |
| 2019 Q2 | 1.34 Million TWD | -24.12% |
| 2018 Q2 | - TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 FY | - TWD | 0.0% |
| 2018 Q1 | - TWD | 0.0% |
| 2018 Q3 | - TWD | 0.0% |
| 2017 Q3 | - TWD | 0.0% |
| 2017 FY | - TWD | 0.0% |
| 2017 Q4 | - TWD | 0.0% |
| 2017 Q2 | - TWD | 0.0% |
| 2017 Q1 | - TWD | 0.0% |
| 2016 Q3 | - TWD | 0.0% |
| 2016 Q4 | - TWD | 0.0% |
| 2016 FY | - TWD | 0.0% |
| 2016 Q1 | - TWD | 0.0% |
| 2016 Q2 | - TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 Q3 | - TWD | -100.0% |
| 2015 Q2 | 359.04 Million TWD | -37.94% |
| 2015 Q1 | 578.54 Million TWD | 0.28% |
| 2015 FY | - TWD | -100.0% |
| 2014 FY | 576.94 Million TWD | 2.43% |
| 2014 Q4 | 576.94 Million TWD | 0.6% |
| 2014 Q3 | 573.48 Million TWD | 0.6% |
| 2014 Q2 | 570.05 Million TWD | 0.6% |
| 2014 Q1 | 566.65 Million TWD | 0.6% |
| 2013 FY | 563.26 Million TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 Q3 | 560.25 Million TWD | 0.0% |
| 2013 Q4 | 563.26 Million TWD | 0.54% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 FY | - TWD | 0.0% |
| 2012 Q1 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2011 Q1 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q3 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 136.36 Million TWD | -520.07% |
| Standard Chem & Pharm CO., LTD. | 222.97 Million TWD | -279.206% |
| Maywufa Company Ltd. | 438.97 Million TWD | -92.613% |
| ScinoPharm Taiwan, Ltd. | 570.23 Million TWD | -48.278% |
| Lotus Pharmaceutical Co., Ltd. | 9.51 Billion TWD | 91.118% |
| LIWANLI Innovation Co., Ltd. | 361 Thousand TWD | -234118.283% |
| YungShin Global Holding Corporation | 241.99 Million TWD | -249.398% |
| PhytoHealth Corporation | 17.46 Million TWD | -4742.658% |
| Formosa Laboratories, Inc. | 2.03 Billion TWD | 58.51% |
| PharmaEssentia Corporation | 954.99 Million TWD | 11.463% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | 75.752% |